CareDx (NASDAQ:CDNA) reported non-GAAP earnings per share of $0.10 in Q2 2025, beating estimates. Adjusted revenue rose 14%, slightly missing expectations. The company maintained its full-year revenue guidance, with $186 million in cash and no debt. CareDx specializes in transplant care solutions, with AlloSure tests for organ rejection. Quarterly performance saw a 14% rise in revenue, driven by test volume growth. Initiatives include EPIC integration and AI-powered diagnostic platforms. Management narrowed revenue guidance to $367 million to $373 million for FY2025. Investors should monitor margin compression, regulatory changes, and infrastructure investments.

Read more at Nasdaq: CareDx (CDNA) EPS Beats Sales Gain 14%